Baxter Ventures identifies companies with promising technologies, products and/or therapies, and provides them with the capital and expertise needed to drive successful innovation. Baxter Ventures was created in 2011 by Baxter International Inc., which has an 80-year legacy of healthcare innovation and saving and sustaining lives worldwide. To learn more visit www.baxter.com
Deerfield is a leading investment management firm committed to advancing healthcare through investment, information and philanthropy.
Deerfield was launched in 1994 with approximately $17 million in capital and, as of January 2014, manages funds in excess of $3.5 billion. It is a relationship-focused, non-activist firm that is committed to helping the companies in which it invests to realize their potential for advancing healthcare and driving change in this crucial industry. Deerfield’s comprehensive understanding of healthcare assets allows it to appreciate opportunity even when complex financial, legislative, regulatory and competitive pressures are present. Collaboration, intellectual curiosity and pragmatism define its approach.
Deerfield has over 70 full-time professionals who bring many decades of experience across all sub-sectors of healthcare in order to deliver innovative funding solutions to the firm’s financing partners. For more information about Deerfield, please visit www.deerfield.com.
Milestone Venture Partners
Milestone Venture Partners is an early stage venture capital fund with $90 million under management. Milestone concentrates on companies that solve business problems and address consumer needs through the innovative application of information technology. Milestone invests approximately 50% of its capital in Digital Health businesses which provide information services to hospitals, physicians, pharmaceutical firms, health plans and consumers. To learn more visit www.milestonevp.com.
New Leaf Venture Partners
NEW LEAF VENTURE PARTNERS is a leading healthcare technology investor, managing approximately $1 billion in funds, and investments in 45 companies. They focus on 3 sectors: biopharmaceuticals, medical devices, and diagnostic/infrastructure technologies. Their goal is to build strong companies by supporting exceptional teams in the development of clinically important and commercially attractive products.
Across all sectors and stages, their investment decisions are primarily driven by a fundamental assessment of the risks in the underlying development programs (i.e., technical, clinical, regulatory, and commercial risks). Before making an investment, they work with the management teams to identify key milestones that must be met to reach points of meaningful value inflection, and they ensure that adequate resources are provided for the company to achieve those milestones.
The NLV investment team has deep operating experience and medical and technical expertise which are integral to their active investment approach. This allows them to work closely with founders, management, and co-investors to identify and execute on a capital efficient and optimal path to value creation and exit. This focused and fundamentals driven investment approach generates attractive returns for their investors.
NLV Partners has offices in New York and Menlo Park, California. They are currently making new investments through New Leaf Ventures II, a $450 million fund, which started its investing cycle in mid-2008. To learn more visit www.nlvpartners.com.
Partnership Fund for New York City
Partnership Fund for New York City is a private fund with a civic mission. The fund was the vision of Henry R. Kravis, founding partner of Kohlberg Kravis Roberts & Co., who serves as its Founding Chairman. His goal was to mobilize the city’s financial and business leaders to help build a stronger and more diversified local economy. To that end, the Fund has built a network of top experts from the investment and corporate communities who help identify and support New York City’s most promising entrepreneurs in both the for-profit and not-for-profit sectors.
The Fund was established in late 1996, under the auspices of the nonprofit The Partnership for New York City. It was initially capitalized by contributions of $1 million each from sixty-seven individual and corporate investors, who invested for the good of the city and without expectation of financial returns. This is a evergreen fund, in which realized gains are reinvested in other worthwhile projects.
The Fund has raised in excess of $110 million. Its investments typically range in size from $1 million to $5 million. The Fund provides equity or debt, structured to meet the needs of the project. It will invest at any stage of business development, but is seeking to exit in about five years. To date, the Fund has invested in more than 100 projects. To learn more visit fund.pfnyc.org.
Safeguard Scientifics provides growth capital for entrepreneurial and innovative life sciences and technology companies. Safeguard targets life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine and Specialty Pharmaceuticals, and technology companies in Internet / New Media, Financial Services IT and Healthcare IT with capital requirements of up to $25 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings.
Safeguard has deployed capital in and provided operational expertise and support to hundreds of companies, entrepreneurs and management teams, successfully completing more than 100 M&A transactions and 20 IPOs. Safeguard’s prudent and innovative approach to identifying market leaders in key strategic sectors has spawned household names and industry leaders including Novell, QVC, Cambridge Technology Partners, Internet Capital Group, CompuCom Systems and Traffic.com. To learn more visit www.safeguard.com.